Twelve-week treatment of tardive dyskinesia with NBI-98854

被引：0
|
作者：
Jimenez, R.
Shiwach, R.
Bari, M.
O'Brien, C. F.
机构：
来源：
MOVEMENT DISORDERS | 2014年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
826
引用
收藏
页码：S304 / S305
页数：2
相关论文
共 50 条
  • [1] RESPONSE TO TREATMENT WITH VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA
    Kane, John
    Josiassen, Richard
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S119 - S119
  • [2] Kinect 2: NBI-98854 treatment of moderate to severe tardive dyskinesia
    O'Brien, C. F.
    Jimenez, R.
    Hauser, R. A.
    Factor, S. A.
    Mandri, D. F.
    Castro-Gyol, J. C.
    [J]. MOVEMENT DISORDERS, 2014, 29 : S305 - S306
  • [3] A Phase 2 Study of Valbenazine (NBI-98854) for Treatment of Tardive Dyskinesia: KINECT 2
    Factor, Stewart
    Hauser, Robert
    Mandri, Daniel
    Castro-Gayol, Julio
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [4] Low incidence of extrapyramidal symptoms in subjects with tardive dyskinesia receiving long-term valbenazine (NBI-98854) treatment
    Lessig, S.
    Kurlan, R.
    Factor, S.
    Burke, J.
    Wright, C.
    Jimenez, R.
    Liang, G.
    [J]. MOVEMENT DISORDERS, 2017, 32
  • [5] VALBENAZINE (NBI-98854) FOR THE TREATMENT OF TARDIVE DYSKINESIA: ANALYSIS BY UNDERLYING PSYCHIATRIC DIAGNOSIS IN PHASE III KINECT 3 STUDY
    Josiassen, Richard
    Kane, John
    Burke, Joshua
    Jimenez, Roland
    Siegert, Scott
    Liang, Grace
    [J]. SCHIZOPHRENIA BULLETIN, 2017, 43 : S217 - S217
  • [6] Open-Label Extension of KINECT: A Phase 2 Study of Valbenazine (NBI-98854) for Tardive Dyskinesia
    Bari, Mohammed
    Shiwach, Raj
    Jimenez, Roland
    Siegert, Scott
    O'Brien, Christopher
    [J]. NEUROLOGY, 2016, 86
  • [7] NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
    O'Brien, Christopher F.
    Jimenez, Roland
    Hauser, Robert A.
    Factor, Stewart A.
    Burke, Joshua
    Mandri, Daniel
    Castro-Gayol, Julio C.
    [J]. MOVEMENT DISORDERS, 2015, 30 (12) : 1681 - 1687
  • [8] Efficacy of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia: Results of a Long-Term Study (KINECT 3 Extension)
    Factor, Stewart
    Comella, Cynthia
    Correll, Christoph
    Liang, Grace
    Burke, Joshua
    O'Brien, Christopher
    [J]. NEUROLOGY, 2017, 88
  • [9] Efficacy of Valbenazine (NBI-98854) in Subjects With Tardive Dyskinesia: Results of a Long-Term Extension Study (KINECT 3 Extension)
    Grigoriadis, Dimitri
    Comella, Cynthia
    Remington, Gary
    Jimenez, Roland
    Burke, Joshua
    Christopher, O'Brien
    [J]. NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S213 - S214
  • [10] EFFICACY AND SAFETY OF VALBENAZINE (NBI-98854) IN SUBJECTS WITH TARDIVE DYSKINESIA: RESULTS OF A LONG-TERM STUDY (KINECT 3 EXTENSION)
    Siegert, S.
    Factor, S.
    Liang, G.
    Burke, J.
    [J]. PARKINSONISM & RELATED DISORDERS, 2018, 46 : E35 - E35
12345